Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AbbVie Ready To Leverage Migraine Franchise In Crowded Market

Qulipta Adds Indication Not Covered By Botox, Ubrelvy

Executive Summary

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

You may also be interested in...



Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next

The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.

Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval

CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel